✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE3
Participants
ALL
Age Range
6 Years+
About This Trial
The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.
Who Can Join?
Inclusion Criteria: * 1. Provision of signed and dated written ICF. 2. Participants completing minimum required OLE period of a parent study and judged by the Investigator to benefit from continued treatment. * 3. Participants must agree to follow the contraception requirements as per their respective parent protocols from study inclusion up to 12 weeks after the last dose of study treatment. * 4. Participants without childbearing potential at enrolment must agree to start appropriate contraception if childbearing potential develops during the study and up to 12 weeks after the last dose of study treatment. * 5. Participants who are unable to access commercially available benralizumab and clinically indicated for continuation. Exclusion Criteria: * 1. Ongoing, unresolved AE requiring interruption of treatment at the end of the prior parent study (ie, when the parent study is either completed or closed) that in the Investigator's opinion would prevent restarting benralizumab. *…
⚠ Always speak to your doctor before applying to any clinical trial.